OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York

Download PDF

NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York, NY.

Details of the Presentations:

Date:           Thursday, February 11
Time:           10:45am Eastern
Room:          Carnegie Suite
Webcast:      http://wsw.com/webcast/leerink26/ohrp 

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.


Ohr Pharmaceutical Inc. 
Investor Relations  

LifeSci Advisors, LLC
Michael Wood

Primary Logo

Source: Ohr Pharmaceutical, Inc.